LEMD2 and glioblastoma: MT1-MMP overexpression would indicate tumor progression towards more aggressive phenotypes associated with a worse prognosis, and also predict that the LEM2/15 antibody would have potential utility as MT1-MMP-targeted PET probe for imaging of GBM.